◀ Back to MMP3

MMP3 — PRG4

Text-mined interactions from Literome

Homandberg et al., Frontiers in bioscience : a journal and virtual library 1999 (Arthritis, Rheumatoid...) : The Fn-fs up-regulate matrix metalloproteinase ( MMP ) expression, significantly enhance degradation and loss of proteoglycan ( PG ) from cartilage and temporarily suppress PG synthesis, all events observed in OA
Sabatini et al., Osteoarthritis Cartilage 2002 : This study shows that PPARgamma agonists inhibit cytokine induced proteoglycan degradation mediated by both aggrecanase and MMP
Boyan et al., Connect Tissue Res 2003 : MMP-3 is also involved in proteoglycan degradation, facilitating calcification
Wako et al., Spine (Phila Pa 1976) 2008 : Introduction of TWEAK resulted in the degradation of disc matrix in organ disc culture, whereas proteoglycan degradation was markedly abrogated in the presence of an MMP-3 specific inhibitor or a JNK inhibitor
Leong et al., Matrix Biol 2010 : Intra-articular injections of an MMP-3 inhibitor, N-isobutyl-N- ( 4-methoxyphenylsulfonyl ) -glycylhydroxamic acid ( NNGH ), dampened the catabolic effects of a 7day immobilization period, indicating a likely requirement for MMP-3 in the regulation of proteoglycan levels through ADAMTS-5
Homandberg et al., Biochem J 1997 : Whereas a 1 nM concentration of an N-terminal 29 kDa fibronectin fragment ( Fn-f ) increases the proteoglycan ( PG ) content of cartilage without induction of matrix metalloproteinases ( MMPs ), 0.1-1 microM Fn-f temporarily suppresses PG synthesis and enhances MMP release